SCHEMBL6735871

SCHEMBL6735871

CS(=O)(=O)c1c(F)cc(-c2cnccc2-c2cccc(OC(F)(F)F)c2)cc1F

nearest known ligand 0.55

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
RPS6KA3 P51812 7/20 0.55
DHODH Q02127 1/20 0.45
SLC22A12 Q96S37 2/20 0.44
DYRK1A Q13627 3/20 0.43
CCNT1 O60563 1/20 0.41
CDK9 P50750 1/20 0.41
NPY5R Q15761 1/20 0.41
DGAT2 Q96PD7 2/20 0.40
GRM2 Q14416 1/20 0.39
CSNK2A2 P19784 1/20 0.39
CSNK2B P67870 1/20 0.39
RXRA P19793 1/20 0.39
NR1H2 P55055 1/20 0.39
NR1H3 Q13133 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7537753 0.88 RPS6KA3 (0.51) RPS6KA3DHODHSLC22A12DYRK1ACCNT1
SCHEMBL6732776 0.88 RPS6KA3 (0.52) RPS6KA3SLC22A12
SCHEMBL6728404 0.83 RPS6KA3 (0.49) RPS6KA3SLC22A12
SCHEMBL6739531 0.83 RPS6KA3 (0.45) RPS6KA3DHODHSLC22A12DYRK1ACCNT1
SCHEMBL6736797 0.83 SLC22A12 (0.58) RPS6KA3SLC22A12
SCHEMBL6734732 0.82 PTGS2 (0.44) DHODH
SCHEMBL6736657 0.82 RPS6KA3 (0.43) RPS6KA3
SCHEMBL6733816 0.82 RPS6KA3 (0.43) RPS6KA3SLC22A12
SCHEMBL6727975 0.82 RPS6KA3 (0.69) RPS6KA3SLC22A12
SCHEMBL6728690 0.81 RPS6KA3 (0.63) RPS6KA3SLC22A12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6699884-B2 ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. PHARMACIA CORPORATION 2004-03-02 US claimed
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-07-15 US disclosed
US-6699884-B2 ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. PHARMACIA CORPORATION 2004-03-02 US disclosed
US-6673818-B2 TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS ARTHRITIS, PAIN, FEVER AND CANCER PHARMACIA CORPORATION 2004-01-06 US disclosed
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-08-07 US disclosed
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-02-13 US disclosed
EP-1251126-A2 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation Pharmacia Corporation (US) 2002-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 RPS6KA3 1600/4885DHODH 2374/4885SLC22A12 4211/4885
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 RPS6KA3 1600/4885DHODH 2374/4885SLC22A12 4211/4885
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 RPS6KA3 1600/4885DHODH 2374/4885SLC22A12 4211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.